Trials / Recruiting
RecruitingNCT07024693
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Design Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DT-168 | Active |
Timeline
- Start date
- 2025-07-30
- Primary completion
- 2026-09-01
- Completion
- 2026-12-01
- First posted
- 2025-06-17
- Last updated
- 2025-12-29
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07024693. Inclusion in this directory is not an endorsement.